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Background: The clinical and prognostic value of programmed death-ligand 1, PD-L1,
in glioblastoma remains controversial. The present study aimed to identify the expression
of PD-L1 for its prognostic value in glioblastoma.
Methods: A comprehensive literature search was performed using the PubMed and
CNKI databases. The overall survival (OS) and disease-free survival (DFS) of GBM was
analyzed based on Hazard ratios (HRs) and 95% confidence intervals (CIs). Furthermore,
Odds ratios (ORs) and 95%CIs were summarized for clinicopathological parameters. The
statistical analysis was using RevMan 5.3 software.
Results: The meta-analysis was performed by using total nine studies including 806
patients who had glioblastoma. The pooled results indicated that PD-L1 expression in
tumor tissues was significantly related to a poor OS (HR = 1.63, 95%CI: 1.19–2.24, P
= 0.003, random effects model) with heterogeneity (I2 = 51%). In subgroup analyses,
PD-L1 positivity was significantly associated with a worse OS for patients of American
and Asian regions, but not for those of European regions. Moreover, PD-L1 expression
implied a trend toward the mutation status of the IDH1 gene [coding the Isocitrate
Dehydrogenase (NADP(+))-1 protein] (HR = 9.92, 95%CI: 1.85–53.08, P = 0.007, fixed
effects model). However, the prediction overall survival (OS) of the patients showed that
PD-L1 expression was independent from other clinicopathological features, such as
gender and age.
Conclusions: Our analyses indicated that high expression of PD-L1 in glioblastoma
tumor tissues is associated with poor survival of patients, and PD-L1 may act as a
prognostic predictor and an effective therapeutic target for glioblastoma.
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INTRODUCTION
Glioblastoma represents the most commonly seen primary
malignant brain tumor in adults, characterized by high
aggressive behavior and high recurrence rate (1). Multimodality
therapies have been suggested and practiced according to
NCCN Guidelines, including surgical resection, radiotherapy
with alkylating agents such as temozolomide (TMZ) and adjuvant
TMZ chemotherapy. However, the outcomes of the treatment
are far from satisfactory with the 5-year overall survival being
<10% (2–4).
Differently from many other tumors, molecularly targeted
therapies for glioblastoma produced very limited advances in
prolonging life expectancies of the patients, reasons at least
partly attributable to the poor penetration of the Blood Brain
Barrier (BBB) by therapeutic agents or by rapidly developing
drug resistance (5, 6). In the recent years, it is increasingly
recognized that the central nervous system (CNS) interacting
actively with the systemic immune system have offered a new
exciting theoretical basis and promising opportunities for brain
tumor immunotherapy (7–10).
Tumor cells can display immune evasion to weaken
antitumor immunity by activating the so-called immune
Checkpoint molecules (ICs) (11). Programmed cell death
ligand-1 (PD-L1), a “classic” IC molecule, has the effect on
induction of T-cell-mediated immune tolerance in tumor local
microenvironment, leading to tumor immune escape and tumor
growth stimulation, by combination with programmed cell
death-1 (PD-1) located on the surface of activated T cells
(12). PD-L1 has been shown to be upregulated in various
cancer cells and associated with unfavorable prognosis (13–
18). Over the past decade, immunotherapies targeting PD-
1/PD-L1 axis have made a series of remarkable breakthroughs
in prognosis improvement of hard-to-treat solid tumors
(including head and neck squamous cell carcinoma, non-
small cell lung cancer, gastric cancer, urothelial cancer, cervical
cancer, and melanoma) and have entered in the standard
clinical practice (19–24). Recently, the expression of PD-L1 on
glioma cells has been documented (25, 26). Researches have
increasingly concerned over the prognostic evaluation of PD-
L1 in patients with glioblastoma. However, whether PD-L1
expression correlates with prognosis in glioblastoma patients
remains controversial. Therefore, we assessed the consistency
and magnitude of the prognostic and clinical significance of
PD-L1 in glioblastoma patients through a systematic review
and meta-analysis.
MATERIALS AND METHODS
Literature Search Strategy
The implementation of this systematic review and meta-
analysis followed the guideline of PRISM, the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses. We
systematically reviewed the literature published in the PubMed
and CNKI (China National Knowledge Infrastructure) databases
(dated to July 2019). The following key words were adopted:
(“glioblastoma” OR “GBM” OR “glioma” OR “brain tumor” OR
“brain cancer” OR “cerebral tumor” OR “intracranial tumor”)
AND (“CD 274” OR “PD-L1” OR “Programmed Cell Death
1 Ligand 1”) without restrictions on languages, regions and
publication types.
Inclusion and Exclusion Criteria
The study adopted the following inclusion criteria: (1) All
patients were diagnosed with glioblastoma by histological
examination; (2) Hazard ratio (HR) and 95% confidence intervals
(CIs) could be available; or the association between PD-L1 and
overall survival (OS) or disease-free survival (DFS) with sufficient
data were provided.
The study excluded the following: (1) conference abstracts,
case reports, reviews, basic research, clinical trials; (2) studies
missing available data.
Data Extraction and Quality Assessment
Two investigators independently reviewed potentially relevant
studies in order to minimize bias. A third reviewer was brought
in when there were disagreements. We extracted the following
data from the included studies: authors, name of the journal, year
of publication and ethnicity, number of enrolled patients, tumor
histology, PD-L1 expression level, cut off value, detection area,
detection methods, and follow-up.
If only survival curves were available, the data could be
extracted from the Kaplan Meier curves. The quality of each
retrieved article was assessed independently by two assessors
according to the Newcastle-Ottawa Quality Assessment Scale
(NOS). A total score of 0–9 was assigned to each included study,
and studies with a NOS score≥5 were considered to be of high
quality (27).
Statistical Analysis
The association between PD-L1 expression with OS and DFS
of patients with glioblastoma was evaluated according to the
HR and 95%CI. Statistical heterogeneity among studies was
quantified with the Cochran’s Q test and the I2 statistic. We
used a random-effects model to pool the data when evidence
suggested significant heterogeneity (I²>50% or P < 0.1), while a
fixed-effects model was conducted otherwise. Subgroup analyses
and sensitivity analyses were attempted to explain the origin
of heterogeneities. The potential publication bias was estimated
by the Begg’s and Egger’s tests with significance of P <
0.05. Review Manager Version 5.3 (Cochrane Collaboration,
Oxford, UK) and STATA 15 were statistical packages used in
the study.
RESULTS
Characteristics of Included Studies
A total of 201 potentially relevant records were obtained
according to the search strategy mentioned above. One hundred
and eighty-eight studies were rejected after screening the
titles and abstracts. Thirteen studies were included for further
evaluation, of which 4 articles without eligible survival data were
excluded. Finally, nine studies with 806 patients fulfilled the
criteria and entered the meta-analysis. The selection flowchart
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FIGURE 1 | Flow chart of the selection process of studies for inclusion in this meta-analysis.
and the baseline information of the studies are, respectively,
displayed in Figure 1 and Table 1.
Association Between PD-L1 Expression
and Prognostic Parameters
PD-L1 Expression and the Overall Survival (OS) of the
Patients
Nine studies presented OS data (n = 806). Significant
heterogeneity existed amongst studies included in the analyses
(I² = 51%, P = 0.04). Pooled result by a random-effects
model revealed a significantly inverse correlation between PD-L1
overexpression and OS of patients with glioblastoma (HR= 1.63,
95% CI: 1.19–2.24, P = 0.003) (Figure 2).
PD-L1 Expression and Association With the Diseases
Free Survival (DFS)
As shown in Figure 3, three studies (n = 299) focused on DFS
and no heterogeneity was existed amongst the studies (I2= 10%,
P= 0.33). However, pooled analysis by fixedmodel did not reveal
any significant link between PD-L1 and DFS of patients (HR =
0.82, 95% CI: 0.58–1.15, P = 0.25).
PD-L1 Expression and Clinicopathological
Characteristics
Age
Two studies, consisting of 246 patients, assessed the correlation
between age and PD-L1 expression. As shown in Figure 4A, 90
(51.14%) of 176 younger patients (whose age defined as younger
than 50 yrs) showed PD-L1 expression, compared with 57.14%
(40 of 70) of older patients (≥ 50 years of age) who had PD-L1
overexpression. PD-L1 expression did not correlate significantly
with age (OR= 0.92, 95% CI: 0.51–1.65, P = 0.78).
Gender
The dependability between PD-L1 expression and gender was
assessed in three studies involving 300 patients. Eighty-five
(52.47%) of 162 male patients and 64 (46.38%) of 138 female
patients were PD-L1 overexpression. The results indicated that
PD-L1 overexpression had no significant association with gender
(OR= 1.20, 95% CI: 0.75–1.92, P = 0.44; Figure 4B).
Ethnicity
In ethnicity subgroup, the stratified analysis revealed PD-
L1 positivity was linked to unfavorable OS in patients
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TABLE 1 | General characteristics of included studies.
References Journal Year Country No. of
patients
Treatment Methods Cut-off point
(high/low)
HR
estimation
Quality
assessment
1 Liu et al. (28) The Journal of
Neuroscience
2013 Denmark 17 Surgery IFC 10–100 positive
cells
OS 6
2 Berghoff et al. (25) Neuro-Oncology 2015 Austria 135 Surgery IHC 5% of positive
cells
OS 7
3 Nduom et al. (29) Neuro-Oncology 2016 USA 94 Surgery IHC 5% of positive
cells
OS 7
4 Zeng et al. (30) Oncotarget 2016 China 229 Surgery IHC 5% of positive
cells
OS +DFS 8
5 Han et al. (31) Journal of Pathology
and Translational
Medicine
2017 Korea 54 Surgery IHC 5% of positive
cells
OS +DFS 8
6 Miyazaki et al. (32) Journal of
Neuro-Oncology
2017 Japan 16 Surgery IHC 50% of positive
cells
OS +DFS 7
7 Lee et al. (33) Journal of
Neuro-Oncology
2017 Korea 115 Surgery IHC 5% of positive
cells
OS 7
8 Pratt et al. (34) Neurosurgery 2018 USA 125 Surgery IHC 5% of positive
cells
OS 8
9 Hwang et al. (35) Journal of
Neuro-Oncology
2018 South
Korea
21 Surgery IHC Score≥2
(infrequent small
clusters of positive
cells)
OS 7
FIGURE 2 | Forest plot of 9 studies evaluating the association between PD-L1 expression and OS in glioblastoma patients.
FIGURE 3 | Forest plot of 3 studies evaluating the association between PD-L1 expression and DFS in glioblastoma patients.
from the Asian regions (five studies with 435 cases: HR =
3.01, 95%CI:1.21–7.48, P = 0.02) and the American regions
(two studies with 219 cases: HR = 2.09, 95% CI:1.48–2.94,
P < 0.0001), but not in patients from the European studies
(two studies with 152 cases: HR = 1.78, 95% CI:0.55–5.81,
P = 0.34) (Figure 5).
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FIGURE 4 | Forest plots for the association of PD-L1 expression with clinicopathological features in glioblastoma patients (A) age; (B) gender.
FIGURE 5 | Forest plot for the association of PD-L1 expression with clinicopathological feature of region in glioblastoma patients.
IDH1 [Isocitrate Dehydrogenase (NADP(+))-1 Coding
Gene] Status
Two separate studies, encompassing 209 patients in total,
evaluated a possible connection between IDH1 mutation
(namely IDH1-wild type vs. with IDH1 mutation) and PD-
L1. Of the 183 tumors which displayed IDH1-wild type, 67
(36.61%) were PD-L1 positive. Of the 26 tumors which had
IDH1-mutantion, one (3.85%) was PD-L1 positive expression.
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FIGURE 6 | Forest plot for the association of PD-L1 expression with clinicopathological feature of IDH1 status in glioblastoma patients.
The pooled OR indicated that PD-L1 positivity was closely
related to IDH1 status (OR = 9.92, 95% CI: 1.85–53.08,
P = 0.007) (Figure 6).
In a subgroup analysis using a random effects model,
heterogeneity was revealed in relation to PD-L1 and ethnicity of
the patients (P < 0.00001, I2 = 91%).
Sensitivity Analysis and Publication Bias
Finally, we found no significant publication bias in the nine
studies entered the current analysis, by, respectively, applying
the Begg’s test and the Egger’s test (P = 0.917 and P = 0.527,
respectively) (Figure 7).
DISCUSSION
PD-L1 is a coinhibitory ligand expressed in many types of tumor
cells. It has been indicated that the binding of PD-L1 to its
receptor PD-1 induces T cell dysfunction and apoptosis which
plays a crucial role in tumor immune evasion. Gliomas have
been recognized as an immunosuppressive tumor. The current
understanding to glioma-mediated immunosuppression have
generated increasing interest in the correlations between PD-L1
expression and survival for gliomas, particularly glioblastomas.
However, the published results about glioblastomas remain
controversial. In 2013 Liu et al. first reported that the expression
of PD-L1 in seventeen patients with glioblastoma is a possible
indicator for poor clinical outcome (28). Using level 3 Illumina
RNASeq, Nduom et al. also found PD-L1 overexpression
was indicative for shorter survival time in 149 patients with
glioblastoma from (data from the Cancer Genome Atlas (TCGA)
dataset) (29). Various other studies showed similar results
(31, 33, 34). However, in a retrospective study of 117 newly
diagnosed glioblastomas as well as a TCGA database analysis
comprising 446 glioblastoma patients, researchersdid not find
a significant connection between PD-L1 and the OS (25).
The similar views were also taken in several other analyses
(30, 32). To clarify a reasonable evidence-based conclusion, a
meta-analysis including 9 studies with a total of 806 patients
was performed. The present meta-analysis showed that PD-L1
positive expression was significantly associated with poor OS
(HR = 1.63, 95% CI: 1.19–2.24, P = 0.003) in glioblastoma
patients after surgery; however, there were insufficient evidence
to suggest that PD-L1 was related to DFS (HR = 0.82,
95% CI: 0.58–1.15, P = 0.25). These results suggested that
FIGURE 7 | Begg’s and Egger’s funnel plot with 95% CI for OS publication
bias in the included nine studies.
PD-L1 positive expression might be a negative prognostic factor
in glioblastomas.
To further explore the potential sources of heterogeneity in the
relationship between PD-L1 and overall survival in glioblastoma,
we utilized subgroup analyses. The results confirmed that the
significance of PD-L1 in OS was not affected by gender and age,
collectively suggesting that this relationship is independent of
these factors in tumor type. The influence of PD-L1 on the OS
of multiethnic patients was also explored. Patients were classified
as from Asia, America and Europe. Different combined HRs
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and P-values for OS were shown in different ethnic groups:
PD-L1 overexpression was significantly associated with poor
OS for patients from Asia and America, while no significant
association for the survival of patients from Europe survival,
which suggested that racial differences may be a potential origin
of heterogeneity in glioblastoma. This “ethnic biasedness” of
PD-L1 has been observed in several clinical studies for patients
with certain other types of solid tumors. KEYNOTE-181, a
phase 3 trial of Pembrolizumab (P) vs. chemotherapy (paclitaxel,
docetaxel or irinotecan) in patients with esophageal squamous
cell carcinoma, showed that P was superior to chemotherapy
for OS in patients with PD-L1 positive expression (CPS≥10)
in the global cohort, especially in the Chinese subgroup (36).
Similarly, in the KEYNOTE-062 (a study of Pembrolizumab
vs. chemotherapy in patients who had advanced gastric or
gastro-esophageal junction cancer), P didn’t bring significant
survival benefits as the first-line treatment for PD-L1-positive
(CPS≥1) population in the full global cohort (37). However,
in further ethnicity subgroup analysis, P showed lower risk
of death in Asians with PD-L1 positive expression (CPS≥1)
when compared to chemotherapy, but not in Europeans,
Americans and Australians. The findings in stratified analyses
revealed that PD-L1 holding a prognostic role in different
ethnic groups may have potential implications inimmunotherapy
and prognostication for stratify patients. It is possible that the
immunogenetics might to some extent differ in different races
(38). So the subgroup analysis stratified by ethnicity may be
necessary for accurately assessing the potential prognostic value
of PD-L1 and the efficacy of relevant immunotherapy drugs in
further clinical studies for glioblastoma.
According to the updated 2016 World Health Organization
(WHO) classification of diffuse gliomas, Isocitrate
dehydrogenase (IDH) has been considered as one of the
important molecular biomarkers that has diagnostic, prognostic
and predictive application (39–42). Studies have reported
that glioblastomas which are hotspot mutation in IDH1
(an isoform of IDH) generally have a significantly better
prognosis compared with IDH1-wildtype glioblastomas (43–
45). Moreover, the expression of PD-L1 in diffuse gliomas
might be directly influenced by IDH1 mutational status
(33, 46, 47). Therefore, the relation between PD-L1 expression
and IDH1 status was further investigated in the stratified
analysis. We found that IDH1-wildtype status in glioblastoma
was PD-L1 expression positive. The result confirmed recent
findings of a PD-L1/IDH1-wildtype association. The hypothesis
about its mechanism of this connection was that IDH1
mutation can result in the PD-L1 promoter hypermethylation
that downregulates the expression of PD-L1 (48, 49). So
the PD-L1 immune checkpoint inhibitors might not be
advisable because of the low PD-L1 expression in patients with
IDH1-mutant glioblastomas.
Recent research has showed that tumor cells in gliomas
can regulate PD-L1 expression via two major mechanisms
to mediate immune evasion, “adaptive resistance” mechanism
and “innate resistance” mechanism (50). The former is for
extrinsic induction of PD-L1. IFN-γ, a proinflammatory cytokine
primarily produced by tumor infiltrating lymphocytes (TILs), can
induce PD-L1 upregulation via NF-κB /PKD2 signal pathway
(51–53). The latter is proved to mediate intrinsic induction of
PD-L1. When there is a lack of TILs, PD-L1 induction in glioma
cells might depend on multiple oncogenic signaling pathways
(such as JAK/STAT 3, PI3K/Akt/mTOR/S6K1 and EGFR/MAPK
pathway) or oncogene mutations (such as ALK, EGFR and
PTEN) (11, 54–60).
It has been indicated that PD-L1may be a valuable therapeutic
target in cancer immunotherapy (9, 61). Recently, promising
preclinical data in murine models of glioma have provided
support for PD-L1 checkpoint inhibitors implementation in
GBM patients (62–64). However, early clinical trials on the
effectiveness of PD-L1 blockade agents are still limited and
elusive. A combination between Anti-PD-L1 mAb durvalumab
and bevacizumab is now being tested in a phase 2 open label,
non-randomized clinical trial for GBM (cohort B, NCT02336165)
(65). Interim results of durvalumab monotherapy revealed low
SAE (severe adverse events) rate of 10% and efficacy with
OS-6 of 42% and PFS-6 (progression-free survival) of 20%.
Trials for other cohorts (cohort A: newly diagnosed MGMT-
promoter unmethylated GBM, cohort C: refractory recurrent
GBM) are still ongoing. Atezolizumab, a humanized antibody
to PD-L1 that has been approved for second-line treatment
for patients with advanced or metastatic NSCLC (non-small
cell lung cancer) and urothelial cancer, is also being studied
in a phase 1a clinical trial for multiple solid tumors, including
GBM (PCD4989g; NCT01375842) (66). Results showed that
Atezolizumab was safe and well-tolerated in patients with GBM.
Glioblastoma was considered a type of “immunologically cold
tumor” due to the relative lack of tumor infiltrating T cells
in the tumor micro-environment (TME) and high selectivity
of BBB (67–69). The “cold” phenotype of GBM may limit
immunotherapy efficacy. Combinatorial treatment approaches
targeting immune-suppression or BBB permeability may help
shift the “cold” microenvironment and enhance response to
immune checkpoint blockade in GBM, including radiation
therapy, chemotherapy, other immunotherapies (e.g., Chimeric
antigen receptor T-cells, oncolytic virus), and bevacizumab (70,
71).
So far as we are aware, the present study is the first meta-
analysis to systematically estimate the correlation between
PD-L1 and clinical outcomes and clinicopathological
factors in glioblastoma. While some limitations need
attention. Firstly, different analysis strategy of IHC and
inconsistent cut-off values of PD-L1 expression may lead
to heterogeneity between studies. Thus, a standardized
approach for protein expression should be set up to improve
consistency and veracity in the measurement of PD-L1
for future studies. Secondly, some subgroups, such as the
IDH1 status group, had small sample sizes. Thirdly, the
investigation about the correlations between PD-L1 and clinical
features, including as tumor size, tumor site and surgical
approach are not performed due to the deficiency of related
original information.
In conclusion, our meta-analysis shows that high PD-L1
expression is strongly correlated with unfavorable prognosis for
GBM patients. PD-L1 may present itself as a valuable target
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for immunotherapy in clinical practice. Additional high-quality,
larger-scale prospective studies are needed to provide validate the
potential value of PD-L1 for the prognosis and treatment of GBM
patients in the future.
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